This promotional content is intended for healthcare professionals in UK only.

Please confirm that you are a healthcare professional in UK.

Decline

This promotional activity has been sponsored by Pfizer Ltd. Pfizer Ltd provided financial support and video content, and has had input into the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchNEUROLOGY.

Vydura®▼ (rimegepant) Prescribing Information (PI) for Great Britain (GB) and Northern Ireland (NI)

Adverse events should be reported. Reporting forms and information can be found at
Adverse events should also be reported to Pfizer Medical Information on 01304 616161

Headache Disorders View Time: 7 mins

touchFEATURE Current oral migraine therapy: targeting calcitonin gene-related peptide (CGRP)

This site is intended for UK healthcare professionals only.

In this series of three short, animated features, learn about the role of CGRP in the pathophysiology of migraine, and how Vydura®▼(rimegepant), a small molecule CGRP receptor antagonist, may help manage this condition.

 
Videos
Vydura® (rimegepant): mode of action

Learn about the burden and pathophysiology of migraine in this short, animated video, and how the small molecule CGRP receptor antagonist Vydura®(rimegepant) works for the acute treatment of migraine or the preventive treatment of migraine.

Adverse Events
Adverse Events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.

 

 

1/3 Next Chapter
 
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised phase 3, double-blind, placebo-controlled trial

Review key clinical trial evidence demonstrating how the small molecule CGRP receptor antagonist Vydura®(rimegepant) can relieve the symptoms of acute migraine.

Adverse Events
Adverse Events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.

2/3 Next Chapter
 
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial

Review key clinical trial evidence demonstrating how the small molecule CGRP receptor antagonist Vydura®(rimegepant) can help prevent migraine in people who have at least 4 migraine attacks per month.

Adverse Events
Adverse Events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.

3/3 Leave Feedback
Leave Feedback
Adverse Events
Adverse Events

Adverse Events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.

Overview & Learning Objectives
Overview

Migraine is a chronic neurovascular disease that affects ~1 billion people worldwide.1 In this series of three short animations, the role of CGRP in the pathophysiology of migraine is explained, and how the small molecule CGRP receptor antagonist Vydura® (rimegepant) works. Vydura® is indicated for:

  • Acute treatment of migraine with or without aura in adults2
  • Preventive treatment of episodic migraine in adults who have at least 4 migraine attacks per month2
Learning Objectives

After watching this activity, participants should be better able to:

  • Understand the role of CGRP in the pathophysiology of migraine
  • Describe how rimegepant, a small molecule CGRP antagonist, can help treat migraine
  • Describe key clinical trial data supporting the use of Vydura® ▼(rimegepant) for the treatment of acute migraine or the prevention of episodic migraine
References
  1. Ashina M, et al. Lancet. 2021;397:1485–1495.
  2. Vydura® (rimegepant) Summary of Products Characteristics for Great Britain, Vydura® (rimegepant) Summary of Products Characteristics for Northern Ireland (NI).
Downloads

View and download resources from this activity to support your learning.

Feedback Close
Feedback

Please provide feedback for this touchFEATURE on the following
(scale of 1-5 where 1=strongly disagree and 5=strongly agree):

* = Mandatory Field

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72